main content start
Xultophy 100/3.6 (insulin degludec and liraglutide injection) combines ultra-long-acting insulin degludec with the glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide and is used to improve blood glucose levels in adults with type 2 diabetes along with diet and exercise. Insulin degludec lowers blood glucose by helping glucose enter the cells to be used as fuel. Liraglutide helps release insulin when blood glucose rises at mealtime, lowers the amount of glucose produced by the liver, and slows the absorption of mealtime glucose.
Xultophy 100/3.6 is approved for adults with type 2 diabetes.
- Xultophy 100/3.6 combines insulin degludec (long-acting insulin) and liraglutide (GLP-1 receptor agonist) to enhance blood glucose management in adults with type 2 diabetes.
- Not for people with type 1 diabetes.
- Given as a once-daily subcutaneous injection.
- Unlike insulin alone, may lead to slight weight loss due to liraglutide’s effect on satiety and gastric emptying.
- Common side effects include: hypoglycemia, nausea, injection site reactions, diarrhea or constipation.
Xultophy 100/3.6 Specs
Key specification
Generic Name
Insulin Degludec/Liraglutide
Drug Class
Insulin + GLP-1 receptor agonists
Type
Injected
General Information
Product Name
Xultophy 100/3.6
Product Type
Injectable Medications
Brand
Novo Nordisk
Other Devices & Supplies
Looking for a different way to manage diabetes care? Browse and compare information on the latest devices, tools, and technology.
